Floatz logo

cd5/cd7 car-t

T Cell Prolymphocytic Leukemia

Essen BiotechCell therapyPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the T Cell Prolymphocytic Leukemia cohort.

Asset / SponsorPhaseRating
Wu-Cart-007
Washington University School of Medicine
Phase 1CC

Same molecule, other indications

cd5/cd7 car-t is also rated in:

T Cell LeukemiaDormant
CCC
Indicative ·
48 / 100
View asset →
T-Cell Lymphoma of CNSDormant
CCC
Indicative ·
48 / 100
View asset →
T Cell Childhood ALLDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →